Methylphenidate and Safinamide Interaction
Drug interaction information between Methylphenidate and Safinamide.
Methylphenidate and Safinamide have a documented major interaction in FDA labeling.
FDA drug labeling documents a major-severity interaction between Methylphenidate and Safinamide. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These drugs both increase certain brain chemicals that can cause your blood pressure to rise to dangerous levels.
What To Do
Avoid using these medications at the same time.
FDA Label Information
Concomitant use of XADAGO with methylphenidate, amphetamine, and their derivatives is contraindicated [see Warnings and Precautions (5.1 , 5.2) ] .
Methylphenidate Also Interacts With
- Dexmethylphenidate moderate
- Risperidone moderate
- Linezolid minor
- Phenelzine minor
- Tranylcypromine minor
Safinamide Also Interacts With
- Tramadol major
- Linezolid major
- Methadone major
- Meperidine major
- Dextromethorphan major
Frequently Asked Questions
Can I take Methylphenidate and Safinamide together?
This is a major interaction. Avoid using these medications at the same time.
How serious is the interaction between Methylphenidate and Safinamide?
This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.
Why do Methylphenidate and Safinamide interact?
These drugs both increase certain brain chemicals that can cause your blood pressure to rise to dangerous levels.
Understanding the Methylphenidate and Safinamide Interaction
FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Methylphenidate belongs to the CNS Stimulant class and Safinamide belongs to the MAO-B Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These drugs both increase certain brain chemicals that can cause your blood pressure to rise to dangerous levels. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Methylphenidate has 11 total documented interactions on file in this dataset, and Safinamide has 10. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid using these medications at the same time. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Methylphenidate or Safinamide based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.